Printer Friendly

FIRST OF TWO RHEOTHRX(R) STUDIES REPORTED: 9,000-PATIENT PHASE III STUDY IN ACUTE MYOCARDIAL INFARCTION PLANNED

 ATLANTA, Nov. 10 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) today announced the presentation of a Phase II trial of RheothRx(R) Injection as an adjunct to coronary angioplasty in the treatment of heart attacks.
 This study is the first of two completed Phase II trials to be reported of RheothRx Injection as a treatment for heart attack.
 The angioplasty study results presented yesterday at the annual meeting of the American Heart Association compared the outcomes of heart attack patients who received RheothRx Injection in addition to acute (primary) coronary angioplasty, with heart attack patients who received placebo in addition to an angioplasty procedure. The results supported the safety profile of the drug though there was no difference in efficacy between the treatment and placebo groups.
 The second study -- which has been submitted for presentation at the March meeting of the American College of Cardiology -- compared outcomes of heart attack patients who received treatment with either of the thrombolytics streptokinase or rt-PA as well as RheothRx Injection, vs. heart attack patients who received only streptokinase or rt-PA. The effects of RheothRx Injection when used with thrombolytics are substantially more promising than when used as an adjunct to acute coronary angioplasty.
 Based on the data generated from these Phase II studies plans are underway for the initiation of a worldwide 9,000 patient Phase III study of RheothRx Injection used alone, or in combination with thrombolytic agents, in patients with acute myocardial infarction. It is anticipated these studies will begin in the first quarter of 1994.
 RheothRx Injection was discovered by scientists at CytRx Corporation and is being developed by Burroughs Wellcome Co. as part of a worldwide licensing agreement.
 CytRx Corporation is engaged in the research and development of critical care pharmaceutical products for the treatment of vascular and infectious diseases, burns and cancer. Vaxcel(TM) a CytRx subsidiary, is developing an advanced adjuvant system for human and veterinary use. CytRx's Vetlife(TM) subsidiary is developing feed additives to enhance growth in feed animals.
 -0- 11/10/93
 /CONTACT: CytRx Corporation, 404-368-9500/
 (CYTR)


CO: CytRx Corporation ST: Georgia IN: MTC SU:

RA-TG -- AT001 -- 2546 11/10/93 07:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1993
Words:358
Previous Article:FOODMAKER REPORTS RESULTS FOR FISCAL 1993
Next Article:DUKE POWER REMINDS CUSTOMERS TO USE FIREPLACES SAFELY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters